MedDataX Logo

Vasodilation Effect of Inhalational Anesthetics

NCT ID: NCT00815269

Last Updated: 2009-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

General Anesthesia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Inhalant anesthetic Vasodilation General anesthesia Ultrasonography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Halothane anesthesia: induction and maintenance with different doses

Group Type ACTIVE_COMPARATOR

Halothane

Intervention Type DRUG

Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen

2

Isoflurane anesthesia: induction and maintenance with different doses

Group Type EXPERIMENTAL

Isoflurane

Intervention Type DRUG

Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

3

Sevoflurane anesthesia: induction and maintenance with different doses

Group Type EXPERIMENTAL

Sevoflurane

Intervention Type DRUG

Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

4

Desflurane anesthesia: induction and maintenance with different doses

Group Type EXPERIMENTAL

Desflurane

Intervention Type DRUG

Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

5

Enflurane anesthesia: induction and maintenance with different doses

Group Type EXPERIMENTAL

Enflurane

Intervention Type DRUG

Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Halothane

Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen

Intervention Type DRUG

Isoflurane

Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

Intervention Type DRUG

Sevoflurane

Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

Intervention Type DRUG

Desflurane

Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

Intervention Type DRUG

Enflurane

Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluothane Forane Sevorane Suprane Ethrane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be undergoing general anesthesia
* Age between 19-45 years

Exclusion Criteria

* With hypertension
* Existing organic dysfunction
* Allergic to inhalant anesthetics
* Alcohol addictive or narcotic dependent patients
* A history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records
Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nanjing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nanjing Medical University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

XiaoFeng Shen, MD

Role: STUDY_DIRECTOR

Nanjing Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nanjing Maternal and Child Health Care Hospital

Nanjing, Jiangsu, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NJFY0812015

Identifier Type: -

Identifier Source: secondary_id

NMU-200812-MZ39

Identifier Type: -

Identifier Source: org_study_id